Skip to main content

Site notifications

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Filter results

You can narrow down the results using the filters

Sponsor

Search

922 result(s) found, displaying 1 to 25
  • AusPAR: Evusheld

    AusPAR for Evusheld (tixagevimab and cilgavimab) for treatment of adults with COVID-19.
  • AusPAR: Kozenis

    AusPAR for Kozenis (tafenoquine) for prevention of relapse of Plasmodium vivax malaria in combination with chloroquine.
  • AusPAR: Nexviazyme

    AusPAR for NEXVIAZYME (avalglucosidase alfa) for long-term enzyme replacement therapy for the treatment of Pompe disease.
  • AusPAR: Truseltiq

    AusPAR for Truseltiq (infigratinib) for treatment of adults with metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.
  • AusPAR: Saphnelo

    AusPAR for SAPHNELO (anifrolumab) as add on treatment of adult patients with moderate to severe, active systemic lupus erythematosus.
  • AusPAR: Utrogestan 200

    AusPAR for Utrogestan 200 (progesterone) for the treatment of unexplained threatened miscarriage in women.
  • AusPAR: Apretude

    AusPAR for Apretude (cabotegravir) for the prevention (to reduce the risk) of sexually acquired HIV-1 infection.
  • AusPAR: Flucelvax Quad

    AusPAR for Flucelvax Quad (quadrivalent influenza vaccine) for the prevention of influenza.
  • AusPar: Spikevax

    AusPAR for SPIKEVAX COVID-19 VACCINE (elasomeran) as booster in 12 to 17 years of age for prevention of COVID-19
  • AusPAR: Verzenio

    New AusPAR for Verzenio (Abemaciclib) for the treatment of patients with HR+, HER2-, node-positive early breast cancer.
  • AusPAR: Xpovio

    New AusPAR for Xpovio (selinexor) for treatment of relapsed or refractory multiple myeloma
  • AusPAR: Ponvory

    For the treatment of adult patients with relapsing forms of multiple sclerosis
  • AusPAR: Yuflyma

    AusPAR for Yuflyma (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis etc.
  • AusPAR: Rybelsus

    AusPAR for Rybelsus (semaglutide) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus.
  • AusPAR: Kimmtrak

    For the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
  • AusPAR: Cosentyx

    AusPAR for Cosentyx (secukinumab) for the treatment of plaque psoriasis, psoriatic arthritis and axial spondyloarthritis etc.
  • Isturisa

    AusPAR for Isturisa (osilodrostat as phosphate) for the treatment of endogenous Cushing’s syndrome in adults.
  • AusPAR: Dazalex SC

    AusPAR for DARZALEX SC (daratumumab) for the treatment of light chain AL amyloidosis
  • AusPAR: Vaxneuvance

    AusPAR for Vaxneuvance (pneumococcal 15-valent conjugate vaccine (CRM197 protein), adsorbed) for the prevention of pneumococcal disease.
  • AusPAR: Tozinameran

    New AusPAR for Comirnaty (tozinameran) for the prevention of COVID-19 in individuals 6 months of age and older.
  • AusPAR: Sogroya

    AusPAR for SOGROYA (somapacitan) indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency.
  • AusPAR: Comirnaty

    AusPAR for COMIRNATY (tozinameran) for the prevention of COVID-19.
  • AusPAR: Lutetium (177Lu) chloride

    AusPAR for Lutetium (177Lu) chloride (lutetium (177Lu) chloride) for the treatment of non-resectable or metastatic neuroendocrine tumours expressing somatostatin subtype 2 receptors when coupled with a suitable carrier molecule.
  • AusPAR: Zeposia

    AusPAR for Zeposia (ozanimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.

Help us improve the Therapeutic Goods Administration site